Department of Didactics and Medical Simulation, Medical University of Lublin, Lublin, Poland.
Department of General, Oncological and Minimally Invasive Surgery, 1st Military Clinical Hospital with the Outpatient Clinic, Lublin, Poland.
Cancer Control. 2020 Jan-Dec;27(1):1073274820903351. doi: 10.1177/1073274820903351.
Colorectal cancer (CRC) is one of the most common cancers worldwide usually diagnosed in the advanced stage. In this study, the serum concentration of tumor endothelial marker 1 (TEM1) was measured and correlated with clinicopathological features to evaluate whether TEM1 might serve as a biomarker for early CRC diagnosis, progression, and prognosis. The concentration of TEM1 was measured in the serum samples of 45 patients with CRC and 35 healthy individuals using enzyme-linked immunosorbent assay test. The mean serum concentration of TEM1 was significantly higher in the patients with CRC compared to the healthy individuals (1.31 ± 0.16 vs 0.92 ± 0.90 ng/mL; < .001). The mean concentration of TEM1 significantly increased in the patients having CRC with early stage (stage I + II) compared to noncancer control individuals (stage I + II vs control 1.21 ± 0.13 ng/mL: 0.92 ± 0.90 ng/mL; < .001). The TEM1 concentration in blood serum also showed a significant association with the development of T stages ( < .001), N stages ( < .001), and M stages ( = .006). The TEM1 sensitivity and specificity in CRC detection are higher than routinely used blood markers (carcinoembryonic antigen [CEA] and carbohydrate antigen [Ca 19-9]). Patients with high TEM1 concentration (≥1.055 ng/mL) had a worse overall survival rate compared to the patients having CRC with low TEM1 concentration (<1.055 ng/mL). In conclusion, TEM1 can act as a potential diagnostic, progression, and prognostic serum biomarker for patients with CRC; TEM1 might be a good supplement for commonly used markers CEA and Ca 19-9.
结直肠癌（CRC）是全球最常见的癌症之一，通常在晚期诊断。在这项研究中，测量了肿瘤内皮标志物 1（TEM1）的血清浓度，并将其与临床病理特征相关联，以评估 TEM1 是否可作为早期 CRC 诊断、进展和预后的生物标志物。使用酶联免疫吸附试验（ELISA）测试测量了 45 例 CRC 患者和 35 名健康个体的血清样本中的 TEM1 浓度。与健康个体相比，CRC 患者的血清 TEM1 平均浓度明显更高（1.31 ± 0.16 与 0.92 ± 0.90 ng/mL；<0.001）。与非癌症对照个体相比，具有早期（I + II 期）CRC 的患者的 TEM1 平均浓度显著升高（I + II 期与对照 1.21 ± 0.13 ng/mL：0.92 ± 0.90 ng/mL；<0.001）。血清中 TEM1 的浓度也与 T 分期（<0.001）、N 分期（<0.001）和 M 分期（=0.006）的发展显着相关。TEM1 在 CRC 检测中的灵敏度和特异性高于常规使用的血液标志物（癌胚抗原[CEA]和碳水化合物抗原[CA 19-9]）。与 TEM1 浓度较低（<1.055 ng/mL）的 CRC 患者相比，TEM1 浓度较高（≥1.055 ng/mL）的患者总体生存率较差。总之，TEM1 可以作为 CRC 患者潜在的诊断、进展和预后的血清生物标志物；TEM1 可能是 CEA 和 CA 19-9 等常用标志物的良好补充。
